Find a Trial

Trial Results


16 protocol(s) meet the specified criteria
A011401OPEN TO ACCRUAL
RANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF WEIGHT LOSS IN ADJUVANT TREATMENT OF OVERWEIGHT AND OBESE WOMEN WITH EARLY BREAST CANCER
A011502OPEN TO ACCRUAL
A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL
CTO-17-101OPEN TO ACCRUAL
Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer
CTO-20190131OPEN TO ACCRUAL
A Phase I, Multicenter, Open-label, Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects with Advanced Solid Tumors
CTO-BTCRC-BRE18-337OPEN TO ACCRUAL
Phase 2 Trial with Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Big Ten Cancer Research Consortium BTCRC-BRE18-337
CTO-EA1181OPEN TO ACCRUAL
EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)
CTO-EAZ171OPEN TO ACCRUAL
Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American women
CTO-M19-345OPEN TO ACCRUAL
A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors
CTO-NCICOVIDOPEN TO ACCRUAL
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
CTO-NYU-S17-00890OPEN TO ACCRUAL
Phase II trial of nivolumab with chemotherapy as neoadjuvant treatment in inflammatory breast cancer (IBC)
CTO-ODO-TE-B202OPEN TO ACCRUAL
A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced or Metastatic Breast Cancer and Tesetaxel Monotherapy in Elderly Patients with HER2 Negative, Locally Advanced or Metastatic Breast Cancer
IUCRO-0514OPEN TO ACCRUAL
Collection Of Specimens And Clinical Data To Create A Biorepository For Metastatic Breast Cancer
NRG-GY006OPEN TO ACCRUAL
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer.
S1609OPEN TO ACCRUAL
DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS
TBCRC044OPEN TO ACCRUAL
A Randomized Phase II Study of Pembrolizumab, an anti-PD (programmed cell death)-1 Antibody, in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease
TBCRCADM-002OPEN TO ACCRUAL
Translational Breast Cancer Research Consortium Biospecimen & Outcomes Repository